Clinicohematologic complete response (CHCR) rates demonstrated that pegylated interferon alpha-2a was the most effective treatment for patients with essential thrombocythemia (ET), according to results of a real-world comparison with hydroxyurea and ruxolitinib in patients with myeloproliferative neoplasms (MPNs) reported in Hematology. The Philadelphia chromosome-negative MPNs (polycythemia vera [PV], ET, and myelofibrosis...
Latest News
BOSTON – Compass Therapeutics, Inc. (OTC:CMPX) provided an update on the clinical development of CTX-009 (also known as ABL001), a dual anti-angiogenic bispecific antibody targeting DLL4 and VEGF-A. A Phase 2a study for CTX-009 in combination with paclitaxel was initiated by Handok Pharmaceuticals, Inc. (KOSDAQ: 002390) in Q1 2021 in...
At the start of the year, pharmacy benefit manager OptumRx predicted that 40% of all new FDA-approved products in 2020 would be orphan drugs. The PBM hasn’t changed that forecast, but it has come out with a bold new prediction about drugs that address small patient populations. Developers of orphan...
LEXINGTON, Mass. — Partner Therapeutics, Inc. (PTx) announced today the publication of a comprehensive review by Mora et al. in the International Journal of Cancer which summarizes the efficacy and safety of anti-GD2 monoclonal antibodies (mAbs) (dinutuximab, dinutuximab beta, and naxitamab) in children with high-risk neuroblastoma when given in combination with Leukine...
OSLO, Norway – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces 21-month follow-up data from the randomized phase I/II trial of ONCOS-102 in combination with standard of care chemotherapy in malignant pleural mesothelioma (MPM). The trial is an open...
Norwood, MA – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, announced topline results from the Phase 3 DETERMINE study of lenabasum in adults with the rare, heterogeneous, autoimmune disease dermatomyositis. Primary endpoint: The study...
MENLO PARK, Calif. — Corcept Therapeutics Inc. (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in GRADIENT, a Phase 3 trial of its...
REDWOOD CITY, Calif. — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the start of BELLA, a Phase 2 trial of relacorilant plus...
REDWOOD CITY, Calif. — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA)...
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of...